Dianthus Therapeutics, Inc. (DNTH) Technical Analysis & Indicators
Dianthus Therapeutics, Inc. (DNTH) — Price $82.70 (closing price, November 3, 2026) — Healthcare — Biotechnology — NASDAQ
Latest reported results:
Technical analysis of Dianthus Therapeutics, Inc. (DNTH): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production,...